Jubilant Ingrevia Q2FY26 Profit Up 18% YoY; EBITDA Rises 8% on Strong Speciality Chemicals Growth

Noida, October 27, 2025 – Jubilant Ingrevia Ltd (NSE: JUBLINGREA, BSE: 543271) recorded a consolidated net profit of ₹70 crore for the quarter ending September 30, 2025, showing an 18% increase compared to the same quarter last year, mainly due to good performance in its Specialty Chemicals segment, as well as improved traction in the Nutrition and Chemical Intermediates business. Jubilant Ingrevia shares closed up 0.037% on Monday.

Key Financial Highlights

During the quarter, the overall revenue for the company was at ₹1,121 crore, exhibiting a year-on-year increase of 7 % and a sequential increase of 8%. The EBITDA was ₹146 crores representing an 8% increase as compared to the same quarter last year and down 5% sequentially. The EBITDA margin remained unchanged at 13%. The profit after tax was ₹70 crores, an 18% increase as compared to the same quarter last year and 7% lower on a sequential basis. The earnings per share were ₹4.4.

For the first half of FY26, Jubilant Ingrevia’s EBITDA increased by 18% to ₹300 crores, while the profit after tax increased by 34% to ₹145 crores, showing operational resilience despite weaker pricing in certain segments.

Segment Performance

Specialty Chemicals Segment

The Specialty Chemicals segment reported revenue of ₹485 crore, registering a 12% year-on-year increase with an EBITDA margin of 26%. Growth was led by Fine Chemicals and CDMO (Contract Development and Manufacturing Organization) operations. During the quarter, the company added over ten new molecules in its CDMO and Fine Chemicals portfolio, which together have the potential to generate more than ₹1,200 crore in annual peak revenue. Pyridine and Diketene derivatives delivered strong double-digit growth, while new agrochemical contracts also began contributing positively.

Nutrition and Health Solutions Segment

In the Nutrition and Health Solutions division, revenue stood at ₹181 crore, down 1% year-on-year, with an EBITDA margin of 12%. The company recorded volume improvement in both Vitamin B3 and Choline (B4) products, though global price pressures limited revenue growth. The European Union’s anti-dumping duty on Chinese-origin Choline opened new market opportunities for Jubilant, which secured its initial European orders during the quarter.

Chemical Intermediates Segment

The Chemical Intermediates segment reported revenue of ₹455 crore, up 6% year-on-year, with an EBITDA margin of 4%. This segment achieved its highest revenue and volume in six quarters, supported by increased sales of Acetic Anhydride and Ethyl Acetate. Jubilant expanded its market share in both domestic and export markets despite ongoing pricing pressures.

Management Commentary

Chairmen Shyam S. Bhartia and Hari S. Bhartia said the company’s Specialty Chemicals business continues to be the key growth driver, with double-digit revenue growth year-on-year. They highlighted that, despite challenging market conditions, Jubilant expanded volumes and maintained profitability, with EBITDA rising 8% YoY and PAT increasing 18%.

Managing Director and CEO Deepak Jain noted that the company achieved its highest quarterly revenue in ten quarters, underscoring the strength of its diversified portfolio. He added that both Specialty and Nutrition segments delivered strong performance, aided by cost efficiencies, expanded R&D capabilities, and new CDMO opportunities.

Operational and Strategic Updates

The company invested ₹59 crore in capital expenditure during Q2FY26, mainly for the upcoming CDMO facility at Bharuch, bringing the total capex for the first half of FY26 to ₹109 crore. Jubilant also increased its renewable energy usage to 28%, which helped lower power and fuel costs by 16% year-on-year. Its Lean Savings Program remains on track to deliver over ₹100 crore in annual efficiency gains. As of September 30, 2025, the company’s net debt stood at ₹748 crore, up 15% from the previous year.

REF: https://nsearchives.nseindia.com/corporate/JUBLINGREA_27102025162152_Investorpresentationintimation_1.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations